Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dosing Observational Study in Hemophilia Subjects With Inhibitors: A Phase IV Diary Study in Subjects Prescribed NovoSeven® as First Line on Demand Therapy for Acute Bleeding Episodes

NCT00710619 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00710619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00710619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dosing Observational Study in Hemophilia Subjects With Inhibitors: A Phase IV Diary Study in Subjects Prescribed NovoSeven® as First Line on Demand Therapy for Acute Bleeding Episodes
Lead sponsor
Novo Nordisk A/S
Phase
Observational
Overall status
Completed
Start date
June 30, 2008
Completion date
July 31, 2009
Enrollment
52 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

congenital bleeding disorder, haemophilia a with inhibitors, haemophilia b with inhibitors